1419223-79-2

Upstream product

• 55557-52-3 2-chloro-3-cyanopyrazine 
• 1419223-12-3 (R)-ethyl 3-(1-(benzyloxycarbonyl)piperidin-3-yl)-8-chloroimidazo[1,5-a]pyrazine-5-carboxylate 
• 1419221-78-5 benzyl (3R)-3-(8-chloroimidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate 
• 1419221-77-4 benzyl (3R)-3-([(3-chloropyrazin-2-yl)methyl]carbamoyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors

The present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.